title: Obesity and polycystic ovary syndrome.
abstract: Obesity is now a major international health concern. It is increasingly common in young women with reproductive, metabolic and psychological health impacts. Reproductive health impacts are often poorly appreciated and include polycystic ovary syndrome (PCOS), infertility and pregnancy complications. PCOS is the most common endocrine condition in women and is underpinned by hormonal disturbances including insulin resistance and hyperandrogenism. Obesity exacerbates hormonal and clinical features of PCOS and women with PCOS appear at higher risk of obesity, with multiple underlying mechanisms linking the conditions. Lifestyle intervention is first line in management of PCOS to both prevent weight gain and induce weight loss; however improved engagement and sustainability remain challenges with the need for more research. Medications like metformin, orlistat, GLP1 agonists and bariatric surgery have been used with the need for large scale randomised clinical trials to define their roles.
authors.affiliation: Monash Centre for Health Research and Implementation School of Public Health and Preventive Medicine Monash University, MHRP, Clayton, Australia - helena.teede@monash.edu.
authors.forename: N
authors.initials: N
authors.lastname: Naderpoor
authors.forename: S
authors.initials: S
authors.lastname: Shorakae
authors.forename: A
authors.initials: A
authors.lastname: Joham
authors.forename: J
authors.initials: J
authors.lastname: Boyle
authors.forename: B
authors.initials: B
authors.lastname: De Courten
authors.forename: H J
authors.initials: HJ
authors.lastname: Teede
mesh_terms: D054392:Adipokines / Q000502:physiology; D050110:Bariatric Surgery; D003131:Combined Modality Therapy; D015897:Comorbidity; D004038:Diet, Reducing; D005081:Exercise Therapy; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000819:agonists; D012739:Gonadal Steroid Hormones / Q000502:physiology; D006801:Humans; D017588:Hyperandrogenism / Q000209:etiology / Q000503:physiopathology; D007249:Inflammation; D007333:Insulin Resistance; D007783:Lactones / Q000627:therapeutic use; D008019:Life Style; D008687:Metformin / Q000627:therapeutic use; D008954:Models, Biological; D009042:Motivation; D009765:Obesity / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology / Q000601:surgery / Q000628:therapy; D056128:Obesity, Abdominal / Q000503:physiopathology; D000077403:Orlistat; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000523:psychology; D015995:Prevalence; D013564:Sympathetic Nervous System / Q000503:physiopathology; D015431:Weight Loss
chemical_list: D054392:Adipokines; D012739:Gonadal Steroid Hormones; D007783:Lactones; D052216:Glucagon-Like Peptide 1; D008687:Metformin; D000077403:Orlistat